Last reviewed · How we verify
AT03
AT03 is a small molecule that targets the [unknown] mechanism.
At a glance
| Generic name | AT03 |
|---|---|
| Also known as | DHP-500 |
| Sponsor | Dhp Korea Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Further research is needed to understand the exact mechanism of action of AT03.
Approved indications
Common side effects
Key clinical trials
- The Impact of Treadmills and Cooler Environments for Office Workplaces on Ergonomics, Heating Energy Requirements, Performance, as Well as Back and Cardiometabolic Health (NA)
- Use of Comfort Theory In Intensive Care (NA)
- mHealth Intervention for Work-Related Stress (NA)
- A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis (PHASE1)
- Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |